Question for written answer
to the Commission
James Nicholson (ECR) (2nd April 2014)
Subject: Special labelling provision for rapeseed protein as a novel food
I welcome the forthcoming authorisation of rapeseed protein as a novel food; however, the draft Commission implementing decision contains an unprecedented labelling provision according to which ‘any foodstuff containing rapeseed protein shall bear an easily visible and legible statement that the product containing “rapeseed protein” as a food ingredient may cause allergic reaction to consumers who are allergic to mustard and products thereof’.
If rapeseed protein is considered an allergen, then it should be listed in Annex II to Regulation (EU) No 1169/2011 on the provision of food information to consumers. If rapeseed protein is not an allergen, it should not be subject to a special labelling requirement.
Will the Commission explain why it has proposed a labelling requirement for allergic cross-reaction as opposed to the traditional professional information channels to inform consumers?
Can the Commission confirm that such a labelling requirement has a legal basis in the current novel foods regulation?
Will the Commission take into consideration the European Food Safety Authority’s anticipated report on the occurrence of food allergies in the EU before imposing unprecedented labelling requirements?
Answer given by Mr Borg on behalf of the Commission (29th April 2014)
The European Food Safety Authority (EFSA) considered in its ‘Scientific Opinion on the safety of “rapeseed protein isolate” as a Novel Food ingredient’, adopted on 10 October 2013, that the risk of sensitisation to rapeseed cannot be excluded and that it is likely that rapeseed can trigger allergic reactions in mustard allergic subjects.
Mustard allergens can cause serious and potentially life-threatening reactions in affected individuals. Potentially exposure to the rapeseed protein is much higher than to mustard as it may replace other protein-rich ingredients in a wide range of foods. This change of protein source will not be immediately evident to the consumer. Rapeseed protein, due to its ‘novel nature’, cannot be considered today as a ‘common allergen’. People with mustard allergies have no reason to avoid the wide range of foods that could contain this novel food ingredient, and they will not be checking the detailed ingredient lists. Therefore, the Commission considers that the most appropriate risk management tool is to provide for a specific labelling requirement instead of using the traditional information channels or the labelling regime applicable to common allergens. The legal basis of such labelling is Article 7(2) in conjunction with Article 8(1)(b) of Regulation (EC) No 258/97.
EFSA is currently reviewing and assessing scientific data on allergenicity in Europe, including the evaluation of the Union list of ‘common allergens’. Once available, the Commission will assess the outcome as well the need for updating the Union legislation accordingly. In this regard, the appropriateness of the inclusion of rapeseed protein in Annex II to Regulation (EU) No 1169/2011 could be considered.
(Source: European Parliament website)